menu
    • menu
    [{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radius Health Divests RAD 140 Program to Ellipses Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Presents Design of Newly Initiated Phase 1\/2a Trial of Vosilasarm (EP0062) at SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Vosilasarm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."}]

    Find Clinical Drug Pipeline Developments & Deals for Vosilasarm

    Menu

    Vosilasarm

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Ellipses Pharma

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABC...

                            Details : EP0062 (vosilasarm) is an oral, non-steroidal, selective androgen receptor modulator (SARM) currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer.

                            Product Name : EP0062

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radius Health

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Radius Health Divests RAD 140 Program to Ellipses Pharma

                            Details : Under the agreement, Ellipses Pharma will be responsible for the clinical development and commercialization of RAD 140. Radius will be entitled to receive royalties on the program as it advances with Elli...

                            Product Name : RAD140

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2020

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth